Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
Authors:
- Karsten-H. WeylandtKWKarsten-H. Weylandt
- Christoph SchmöckerCSChristoph Schmöcker
- Annika I. OstermannAOAnnika I. Ostermann
- Laura KutznerLKLaura Kutzner
- Ina WillenbergIWIna Willenberg
- Stefanie KieslerSKStefanie Kiesler
- Elisabeth Steinhagen-ThiessenESElisabeth Steinhagen-Thiessen
- Nils Helge SchebbNSNils Helge Schebb
- Ursula KassnerUKUrsula Kassner
Open Access
Abstract
Lipoprotein apheresis reliably reduces low-density lipoprotein (LDL) cholesterol in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). Besides lowering lipoproteins and triglycerides, apheresis also decreases levels of essential omega-6 and omega-3 polyunsaturated fatty acids (n-6 and n-3 PUFAs) in blood plasma. In contrast, heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) lipid apheresis might increase the formation of potentially pro-inflammatory and pro-thrombotic lipid mediators derived from n-6 and n-3 PUFAs. The study presented here analyzed lipid mediator profiles in the plasma of patients with hyperlipidemia treated by one of three different apheresis methods, either HELP, direct absorption (DA), or membrane filtration (MDF), in a direct pre- and post-apheresis comparison. Using gas chromatography and liquid chromatography tandem mass spectrometry (LC-MS/MS) we were able to analyze fatty acid composition and the formation of lipid mediators called oxylipins. Our data illustrate—particularly in HELP-treated patients—significant decreases of essential omega-6 and omega-3 polyunsaturated fatty acids in blood plasma but significant increases of PUFA-derived lipoxygenase-, as well as cyclooxygenase- and cytochrome P450-derived lipid mediators. Given that n-3 PUFAs in particular are presumed to be cardioprotective and n-3 PUFA-derived lipid mediators might limit inflammatory reactions, these data indicate that n-3 PUFA supplementation in the context of lipid apheresis treatment might have additional benefits through apheresis-triggered protective n-3 PUFA-derived lipid mediators.Keywords
This publication has 40 references indexed in Scilit:
- Transient heparin-induced platelet activation linked to generation of platelet 12-lipoxygenaseThrombosis and Haemostasis, 2013
- Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls painThe FASEB Journal, 2012
- LDL-Apheresis: Technical and Clinical AspectsThe Scientific World Journal, 2012
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering TherapyCirculation, 2011
- n–3 Fatty Acids in Cardiovascular DiseaseNew England Journal of Medicine, 2011
- Sustained Inhibition of Oxidized Low-Density Lipoprotein Is Involved in the Long-Term Therapeutic Effects of Apheresis in Dialysis PatientsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Cardiovascular Events in Patients with Increased Lipoprotein (a) – Retrospective Data Analysis in an Outpatient Department of Lipid DisordersAtherosclerosis Supplements, 2009
- Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biologyJournal of Lipid Research, 2009
- The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic DiseasesExperimental Biology and Medicine, 2008
- 12/15-Lipoxygenase Regulates Intercellular Adhesion Molecule-1 Expression and Monocyte Adhesion to Endothelium Through Activation of RhoA and Nuclear Factor-κBArteriosclerosis, Thrombosis, and Vascular Biology, 2005